



# **Preventive Services Guide**

Effective January 1, 2024

### **Preventive Care Guide**

**Overview (Federal Preventive Care Requirements):** The federal Patient Protection and Affordable Care Act (PPACA) requires non-grandfathered health plans to cover certain services under preventive care, without cost sharing to members when provided by an in-network provider. This coverage includes:

- Evidence-based items or services that have in effect a rating of "A" or "B" in the current recommendations of the United States Preventive Services Task Force (USPSTF).
  - Published USPSTF A/B recommendations can be found at: <u>https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations</u>
- Immunizations for routine use in children, adolescents and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).
  - Published ACIP recommended immunization schedules can be found at: <u>https://www.cdc.gov/vaccines/schedules/hcp/index.html</u>
- With respect to infants, children and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA). HRSA endorses preventive guidelines established by the American Academy of Pediatrics (AAP) for the health and well-being of infants, children and adolescents. These recommendations are referred to as Bright Futures.
  - Published Bright Futures recommendations can be found at: <u>https://downloads.aap.org/AAP/PDF/periodicity\_schedule.pdf</u>
- With respect to women, such additional preventive care and screenings as provided for in comprehensive guidelines supported by the HRSA.
  - Published HRSA recommendations (for women) can be found at: <u>https://www.hrsa.gov/womens-guidelines</u>

Note: Coverage of preventive care services must become effective upon a plan's start or anniversary date that is one year after the date a new recommendation or guideline is issued.

PPACA states reasonable medical management techniques may be used to determine coverage limitations if a recommendation or guideline does not specify the frequency, method, treatment, or setting for the provision of a recommended preventive service. Reasonable medical management techniques may include precertification, concurrent review, claim review, or similar practices to determine coverage limitations under the plan. These established reasonable medical management techniques and practices may be utilized to determine frequency, method, treatment or setting for the provision of a recommended preventive service.

In addition to the designated services identified by the above-listed sources, tobacco cessation treatment, wellness examinations for all populations – children and adults – and services that are integral to the furnishing of a specific preventive care benefit (e.g., anesthesia provided during sterilization surgery for women) are included under preventive care coverage.

Ambetter Preventive Care Coverage: All Ambetter plans provide preventive care coverage in accordance with the above-listed PPACA requirements. If two recommendations address the same benefit, but differ (e.g., USPSTF's breast cancer screening recommendation vs. HRSA's breast cancer screening recommendation), the richest coverage applies. Although this documentation only focuses on federal requirements (national preventive care coverage), we do cover additional preventive care benefits when required by state law.

Preventive care refers to measures or services taken to promote health and early detection/prevention of diseases and injuries, rather than treating them or curing them. Preventive care may include, but is not limited to, examinations and screening tests tailored to an individual's age, health, and family history. All preventive care received from an in-network Ambetter provider is covered with no cost share (i.e., covered at 100% (of the contracted amount) – without deductible, coinsurance or copayment).

Please keep in mind, certain covered services can be provided for preventive or diagnostic reasons. When a covered preventive service is performed for the purpose of preventive screening and is appropriately reported (billed by the provider), it will fall under the preventive care services benefit. This includes services directly related to the performance of a covered preventive care service. Examples of preventive services are those performed on a person who:

- Has not had the preventive screening done before and does not have symptoms or other abnormal studies suggesting abnormalities; or
- Has had the preventive screening done within the recommended interval with the findings considered normal; or
- Has had diagnostic services results that were normal after which the physician recommendation would be for future preventive screening studies using the preventive services intervals.

However, when a covered service is performed for diagnostic purposes, it will not fall under preventive care, but rather under the applicable non-preventive medical benefit. Examples of diagnostic services are those performed on a person who:

- Had abnormalities found on previous preventive or diagnostic studies that require further diagnostic studies; or
- Had abnormalities found on previous preventive or diagnostic studies that would recommend a repeat of the same studies within shortened time intervals from the recommended preventive screening time intervals; or
- Had a symptom(s) that required further diagnosis; or
- Does not fall within the applicable population for a recommendation or guideline.

The following table (beginning on page 3) provides an overview of available preventive care coverage. IMPORTANT: If a preventive care service is recommended for a specific gender (e.g., men or women), this is in reference to the individual's sex assigned at birth, rather than gender identity.

#### Acronyms:

- •AAP: American Academy of Pediatrics
- •ACIP: Advisory Committee on Immunization Practices
- •CDC: Centers for Disease Control & Prevention
- •EOC: Evidence of Coverage

- •HRSA: Health Resources & Services Administration
- •PPACA: Patient Protection & Affordable Care Act
- •USPSTF: United States Preventive Services Task Force
- •WPSI: Women's Preventive Services Initiative

**Member Questions:** For any questions regarding preventive care coverage, please talk to your physician directly or call us at the toll-free number listed on the back of your Ambetter ID card.

|   | PREVENTIVE   | E CARE SERVICES  |
|---|--|--|
| (Newborns, Children, Adolescents and Adults)                                  |  |  |
| Service   | Population   | Summary  |
| Wellness Examinations   | Children and Adults  | <ul> <li>Preventive medicine comprehensive evaluation and<br/>management services (i.e., wellness examinations) for well-<br/>baby, well-child and well-adult/woman include:</li> <li>An age-and gender-appropriate history,</li> <li>Physical examination,</li> <li>Counseling/anticipatory guidance,</li> <li>Risk factor reduction interventions, and</li> <li>The ordering of appropriate immunization(s) and<br/>laboratory/screening procedures.</li> <li>Note: The below-listed services may be provided as part of a<br/>wellness examination or at a separate encounter.</li> </ul> |
|   | USPSTF's A/B   | Recommendations  |
| Abdominal Aortic Aneurysm<br>Screening  | Men  | <b>USPSTF Rating (Dec. 2019): B</b><br>The USPSTF recommends 1-time screening for abdominal<br>aortic aneurysm with ultrasonography in men aged 65-75<br>years who have ever smoked.   |
| Anxiety Screening in Children and Adolescents                                 | Children and<br>Adolescents  | <b>USPSTF Rating (Oct. 2022): B</b><br>The USPSTF recommends screening for anxiety in children<br>and adolescents aged 8 to 18 years.  |
| Aspirin Use to Prevent<br>Preeclampsia and Related<br>Morbidity and Mortality | Pregnant Women   | USPSTF Rating (Sept. 2021): B<br>The USPSTF recommends the use of low-dose aspirin (81<br>mg/day) as preventive medication after 12 weeks of<br>gestation in persons who are at high risk for preeclampsia.  |
| Bacteriuria Screening   | Pregnant Women   | USPSTF Rating (Sept. 2019): B<br>The USPSTF recommends screening for asymptomatic<br>bacteriuria using urine culture in pregnant persons.  |
| Behavioral Counseling to<br>Prevent Sexually Transmitted<br>Infections        | Adolescents and<br>Adults  | USPSTF Rating (Aug. 2020): B<br>The USPSTF recommends behavioral counseling for all<br>sexually active adolescents and for adults who are at<br>increased risk for sexually transmitted infections (STIs).   |
| Behavioral Counseling to<br>Prevent Skin Cancer                               | Children, Adolescents,<br>Young Adults and<br>Parents of Young<br>Children | USPSTF Rating (March 2018): B<br>The USPSTF recommends counseling young adults,<br>adolescents, children and parents of young children about<br>minimizing exposure to ultraviolet (UV) radiation for persons<br>ages 6 months to 24 years with fair skin types to reduce<br>their risk of skin cancer.  |
| Breast Cancer Screening   | Women  | USPSTF Rating (Jan. 2016): BThe USPSTF recommends biennial screening mammographyfor women aged 50 to 74 years.Note: Please also refer to the HRSA breast cancer screeningrecommendation on page 10; it addresses richer coverage(beginning at age 40).   |

| PREVENTIVE CARE SERVICES  |            |   |
|---|------------|---|
| (Newborns, Children, Adolescents and Adults)  |            |   |
| Service   | Population | Summary   |
| Cervical Cancer Screening   | Women      | USPSTF Rating (Aug. 2018): A<br>The USPSTF recommends screening for cervical cancer every<br>3 years with cervical cytology alone in women aged 21-29<br>years.   |
|   |            | <ul> <li>For women 30 to 65 years of age, the USPSTF recommends:</li> <li>Screening every 3 years with cervical cytology (pap test) alone,</li> <li>Every 5 years with high-risk human papillomavirus</li> </ul>  |
|   |            | <ul> <li>Every 5 years with high-lisk human paphiomavitus<br/>(hrHPV) testing alone, or</li> <li>Every 5 years with hrHPV testing in combination</li> </ul>   |
|   |            | with cytology (cotesting).  |
| Chlamydia Infection<br>Screening  | Women      | USPSTF Rating (Sept. 2021): B<br>The USPSTF recommends screening for chlamydia in all<br>sexually active women 24 years or younger and in women 25<br>years or older who are at increased risk for infection. This<br>recommendation applies to asymptomatic, sexually active<br>adolescents and adults, including pregnant persons.  |
| Cholesterol Screening (Lipid<br>Disorders Screening) / Statin<br>Use for the Primary<br>Prevention of Cardiovascular<br>Disease in Adults | Adults     | <ul> <li>USPSTF Rating (Aug. 2022): B</li> <li>The USPSTF recommends that adults without a history of cardiovascular disease (CVD) use a low to moderate dose statin for the prevention of CVD events and mortality when all the following criteria are met: <ul> <li>They are aged 40 to 75 years;</li> <li>They have 1 or more CVD risk factors (such as, dyslipidemia, diabetes, hypertension or smoking); and</li> <li>They have a calculated 10-year risk of a cardiovascular event of 10% or greater.</li> </ul> </li> <li>Note: Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in</li> </ul> |
| Colorectal Cancer Screening   | Adults     | adults aged 40 to 75 years.USPSTF Rating (May 2021): BThe USPSTF recommends screening for colorectal cancer in<br>adults aged 45 to 49 years.USPSTF Rating (May 2021): AThe USPSTF recommends screening for colorectal cancer in<br>all adults aged 50 to 75 years.Several recommended screening tests are available.<br>Clinicians and patients may consider a variety of factors in<br>deciding which testing approach is best for each person.   |

| PREVENTIVE CARE SERVICES   |                      |   |
|--|----------------------|---|
| (Newborns, Children, Adolescents and Adults)   |                      |   |
| Service  | Population           | Summary   |
|  |                      | <ul> <li>Recommended intervals* for colorectal cancer screening tests include: <ul> <li>High-sensitivity guaiac fecal occult blood test (HSgFOBT) or fecal immunochemical test (FIT) every year,</li> <li>Stool DNA-FIT every 1 to 3 years,</li> <li>Computed tomography colonography every 5 years,</li> <li>Flexible sigmoidoscopy every 5 years,</li> <li>Flexible sigmoidoscopy every 10 years + annual FIT, and</li> <li>Colonoscopy screening every 10 years.</li> </ul> </li> <li>*IMPORTANT: If a follow-up colonoscopy is required due to a positive non-invasive stool-based screening test or direct visualization screening test for colorectal cancer, the follow-up colonoscopy screening is also considered preventive care (covered without cost share when provided by an innetwork provider). Per the USPSTF, "the follow-up colonoscopy is an integral part of the preventive screening without which the screening would not be complete."</li> </ul> |
| Fluoride Application in<br>Primary Care (Prevention of<br>Dental Caries in Children<br>Younger than 5 Years) | Infants and Children | <ul> <li>USPSTF Rating (Dec. 2021): B</li> <li>The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.</li> <li>USPSTF Rating (Dec. 2021): B</li> <li>The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.</li> </ul>  |
| Folic Acid for the Prevention<br>of Neural Tube Defects  | Women                | USPSTF Rating (Aug. 2023): A<br>The USPSTF recommends that all persons planning to or<br>who could become pregnant take a daily supplement<br>containing 0.4 to 0.8 mg (400 to 800 μg) of folic acid.   |
| Genetic Counseling and<br>Evaluation for BRCA Testing<br>and BRCA Lab Screening                              | Women                | USPSTF Rating (Aug. 2019): B<br>The USPSTF recommends that primary care clinicians assess<br>women with a personal or family history of breast, ovarian,<br>tubal, or peritoneal cancer or who have an ancestry<br>associated with breast cancer susceptibility 1 and 2<br>(BRCA1/2) gene mutations with an appropriate brief familial<br>risk assessment tool.<br>Women with a positive result on the risk assessment tool<br>should receive genetic counseling and, if indicated after<br>counseling, genetic testing.  |

|   | PREVENTIV                 | E CARE SERVICES  |
|---|---------------------------|--|
| (Newborns, Children, Adolescents and Adults)  |                           |  |
| Service   | Population                | Summary  |
| Gestational Diabetes<br>Screening   | Pregnant Women            | USPSTF Rating (Aug. 2021): B<br>The USPSTF recommends screening for gestational diabetes<br>mellitus in asymptomatic pregnant persons at 24 weeks of<br>gestation or after.  |
| Gonorrhea Screening   | Women                     | USPSTF Rating (Sept. 2021): B<br>The USPSTF recommends screening for gonorrhea in all<br>sexually active women 24 years or younger and in women 25<br>years or older who are at increased risk for infection. This<br>recommendation applies to asymptomatic, sexually active<br>adolescents and adults, including pregnant persons.   |
| Healthy Diet and Physical<br>Activity for Cardiovascular<br>Disease Prevention in Adults<br>with Cardiovascular Risk<br>Factors: Behavioral<br>Counseling Interventions | Adults                    | <b>USPSTF Rating (Nov. 2020): B</b><br>The USPSTF recommends offering or referring adults with<br>cardiovascular disease risk factors to behavioral counseling<br>interventions to promote a healthy diet and physical activity.   |
| Healthy Weight and Weight<br>Gain During Pregnancy:<br>Behavioral Counseling<br>Interventions   | Pregnant Women            | USPSTF Rating (May 2021): B<br>The USPSTF recommends that clinicians offer pregnant<br>persons effective behavioral counseling interventions aimed<br>at promoting healthy weight gain and preventing excess<br>gestational weight gain in pregnancy.  |
| Hepatitis B Virus Infection<br>Screening  | Adolescents and Adults    | USPSTF Rating (July 2019): A<br>The USPSTF recommends screening for hepatitis B virus<br>(HBV) infection in pregnant women at their first prenatal<br>visit.<br>USPSTF Rating (Dec. 2020): B   |
|   |                           | The USPSTF recommends screening for hepatitis B virus<br>(HBV) infection in adolescents and adults at high risk for<br>infection.  |
| Hepatitis C Virus Infection<br>Screening  | Adults                    | USPSTF Rating (March 2020): B<br>The USPSTF recommends screening for hepatitis C virus<br>infection in adults aged 18-79 years.  |
| Human Immunodeficiency<br>Virus (HIV) Screening   | Adolescents and<br>Adults | <ul> <li>USPSTF Rating (June 2019): A</li> <li>The USPSTF recommends that clinicians screen for HIV infection in: <ul> <li>Adolescents and adults aged 15-65 years.</li> <li>Younger adolescents and older adults who are at increased risk of infection should also be screened.</li> <li>All pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.</li> </ul> </li> </ul> |
| Interventions for Tobacco<br>Smoking Cessation in Adults,<br>including Pregnant Persons   | Adults                    | USPSTF Rating (Jan. 2021): A<br>The USPSTF recommends that clinicians ask all pregnant<br>persons about tobacco use, advise them to stop using<br>tobacco, and provide behavioral interventions for cessation<br>to pregnant persons who use tobacco.  |

|   | PREVENTIVI | E CARE SERVICES  |
|---|------------|--|
| (Newborns, Children, Adolescents and Adults)  |            |  |
| Service   | Population | Summary  |
|   |            | <b>USPSTF Rating (Jan. 2021): A</b><br>The USPSTF recommends that clinicians ask all adults about<br>tobacco use, advise them to stop using tobacco, and provide<br>behavioral interventions and US Food and Drug<br>Administration (FDA) approved pharmacotherapy for<br>cessation to nonpregnant adults who use tobacco. |
| Latent Tuberculosis<br>Infection: Screening   | Adults     | USPSTF Rating (Sept. 2016): B<br>The USPSTF recommends screening for latent tuberculosis<br>infection (LTBI) in populations at increased risk. This<br>recommendation applies to asymptomatic adults 18 years<br>and older at increased risk for tuberculosis.   |
| Medication Use to Reduce<br>Risk of Breast Cancer   | Women      | <b>USPSTF Rating (Sept. 2019): B</b><br>The USPSTF recommends that clinicians offer to prescribe<br>risk reducing medications, such as tamoxifen, raloxifene, or<br>aromatase inhibitors, to women who are at increased risk<br>for breast cancer and at low risk for adverse medication<br>effects.                       |
| Newborn Screenings<br>(Hypothyroidism,<br>Phenylketonuria Screening<br>and Sickle Cell Screening) | Newborns   | USPSTF Rating (March 2008): A<br>Hypothyroidism Screening: Screening for congenital<br>hypothyroidism in newborns (0-90 days).<br>USPSTF Rating (March 2008): A  |
|   |            | <ul> <li>Phenylketonuria Screening: Screening for phenylketonuria<br/>(PKU) in newborns (0-90 days).</li> <li>USPSTF Rating (Sept. 2007): A<br/>Sickle Cell Screening: Screening for sickle cell disease in<br/>newborns (0-90 days).</li> </ul>   |
| Ocular Prophylaxis for<br>Gonococcal Ophthalmia<br>Neonatorum                                     | Newborns   | USPSTF Rating (Jan. 2019): A<br>The USPSTF recommends prophylactic ocular topical<br>medication for all newborns to prevent gonococcal<br>ophthalmia neonatorum.   |
| Osteoporosis Screening  | Women      | <b>USPSTF Rating (June 2018): B</b><br>The USPSTF recommends screening for osteoporosis with<br>bone measurement testing to prevent osteoporotic<br>fractures in women 65 years and older.   |
|   |            | <b>USPSTF Rating (June 2018): B</b><br>The USPSTF recommends screening for osteoporosis with<br>bone measurement testing to prevent osteoporotic<br>fractures in postmenopausal women younger than 65 years<br>who are at increased risk of osteoporosis, as determined by<br>a formal clinical risk assessment tool.      |

|  | PREVENTIV                        | E CARE SERVICES  |
|--|----------------------------------|--|
| (Newborns, Children, Adolescents and Adults)   |                                  |  |
| Service  | Population                       | Summary  |
| Perinatal Depression –<br>Preventive Interventions<br>(Counseling)                           | Pregnant and<br>Postpartum Women | USPSTF Rating (Feb. 2019): B<br>The USPSTF recommends that clinicians provide or refer<br>pregnant and postpartum persons who are at increased risk<br>of perinatal depression to counseling interventions.  |
| Preeclampsia Screening   | Pregnant Women                   | <b>USPSTF Rating (April 2017): B</b><br>The USPSTF recommends screening for preeclampsia in<br>pregnant women with blood pressure measurements<br>throughout pregnancy.  |
| Prevention of Falls in<br>Community-Dwelling Older<br>Adults                                 | Adults                           | USPSTF Rating (April 2018): B<br>The USPSTF recommends exercise interventions to prevent<br>falls in community-dwelling adults 65 years or older who are<br>at increased risk for falls.   |
| Prevention of Human<br>Immunodeficiency Virus<br>(HIV) Infection: Preexposure<br>Prophylaxis | Adolescents and<br>Adults        | <b>USPSTF Rating (Aug. 2023): A</b><br>The USPSTF recommends that clinicians offer preexposure<br>prophylaxis (PrEP) with effective antiretroviral therapy to<br>persons who are at high risk of HIV acquisition.  |
|  |                                  | <ul> <li>Includes related benefits:</li> <li>Kidney function testing (creatinine),</li> <li>Serologic testing for hepatitis B and C virus,</li> <li>Testing for other STIs,</li> <li>Pregnancy testing when appropriate and</li> <li>Ongoing follow-up and monitoring, including HIV testing every 3 months.</li> </ul>        |
| Primary Care Interventions<br>to Prevent Tobacco Use in<br>Children and Adolescents          | Children and<br>Adolescents      | <ul> <li>USPSTF Rating (April 2020): B</li> <li>The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.</li> <li>Bright Futures recommends tobacco use assessments from</li> </ul> |
| Primary Care Interventions<br>to Promote Breastfeeding                                       | Pregnant and<br>Postpartum Women | age 11-21 years.<br>USPSTF Rating (Oct. 2016): B<br>The USPSTF recommends providing interventions during   |
| Rh(D) Incompatibility<br>Screening   | Pregnant Women                   | <ul> <li>pregnancy and after birth to support breastfeeding.</li> <li>USPSTF Rating (Feb. 2004): A</li> <li>The USPSTF recommends Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy related care.</li> </ul>  |
|  |                                  | <b>USPSTF Rating (Feb. 2004): B</b><br>The USPSTF recommends repeated Rh (D) antibody testing<br>for all unsensitized Rh (D)-negative women at 24-28 weeks<br>gestation, unless the biological father is known to be Rh (D)-<br>negative.  |

|   | PREVENTIV                   | 'E CARE SERVICES  |
|---|-----------------------------|---|
| (Newborns, Children, Adolescents and Adults)  |                             |   |
| Service   | Population                  | Summary   |
| Screening and Behavioral<br>Counseling Interventions in<br>Primary Care to Reduce<br>Unhealthy Alcohol Use in<br>Adults | Adults                      | USPSTF Rating (Nov. 2018): B<br>The USPSTF recommends screening for unhealthy alcohol<br>use in primary care settings in adults 18 years or older,<br>including pregnant women, and providing persons engaged<br>in risky or hazardous drinking with brief behavioral<br>counseling interventions to reduce unhealthy alcohol use.  |
| Screening for Anxiety<br>Disorders in Adults  | Adults                      | USPSTF Rating (June 2023): B<br>The USPSTF recommends screening for anxiety disorders in<br>adults (64 years or younger), including pregnant and<br>postpartum persons.   |
| Screening for Depression in<br>Adults   | Adults                      | USPSTF Rating (June 2023): B<br>The USPSTF recommends screening for depression in the<br>general adult population, including pregnant and<br>postpartum women. Screening should be implemented with<br>adequate systems in place to ensure accurate diagnosis,<br>effective treatment, and appropriate follow-up.   |
| Screening for Depression in<br>Children and Adolescents   | Adolescents                 | USPSTF Rating (Oct. 2022): B<br>The USPSTF recommends screening for major depressive<br>disorder (MDD) in adolescents aged 12 -18 years. Screening<br>should be implemented with adequate systems in place to<br>ensure accurate diagnosis, effective treatment, and<br>appropriate follow-up.  |
| Screening for High Blood<br>Pressure (Hypertension) in<br>Adults  | Adults                      | USPSTF Rating (April 2021): A<br>The USPSTF recommends screening for hypertension in<br>adults 18 years or older with office blood pressure<br>measurement. The USPSTF recommends obtaining blood<br>pressure measurements outside of the clinical setting for<br>diagnostic confirmation before starting treatment.  |
| Screening for Intimate<br>Partner Violence  | Women                       | USPSTF Rating (Oct. 2018): B<br>The USPSTF recommends that clinicians screen for intimate<br>partner violence in women of reproductive age and provide<br>or refer women who screen positive to ongoing support<br>services.  |
| Screening for Lung Cancer<br>with Low-Dose Computed<br>Tomography   | Adults                      | USPSTF Rating (March 2021): B<br>The USPSTF recommends annual screening for lung cancer<br>with low dose computed tomography (LDCT) in adults aged<br>50 to 80 years who have a 20 pack-year smoking history and<br>currently smoke or have quit within the past 15 years.<br>Screening should be discontinued once a person has not<br>smoked for 15 years or develops a health problem that<br>substantially limits life expectancy or the ability or<br>willingness to have curative lung surgery. |
| Screening for Obesity in<br>Children and Adolescents  | Children and<br>Adolescents | USPSTF Rating (June 2017): B<br>The USPSTF recommends that clinicians screen for obesity ir<br>children and adolescents 6 years and older and offer or refe   |

|   | PREVENTIV                 | 'E CARE SERVICES   |
|---|---------------------------|--|
| (Newborns, Children, Adolescents and Adults)  |                           |  |
| Service   | Population                | Summary  |
|   | -                         | them to comprehensive, intensive behavioral interventions to promote improvements in weight status.  |
| Screening for Pre-Diabetes<br>and Type 2 Diabetes   | Adults                    | USPSTF Rating (Aug. 2021): B<br>The USPSTF recommends screening for prediabetes and type<br>2 diabetes in adults aged 35 to 70 years who are overweight<br>or obese. Clinicians should offer or refer patients with<br>prediabetes to effective preventive interventions.  |
| Screening for Visual<br>Impairment in Children  | Children                  | USPSTF Rating (Sept. 2017): B<br>The USPSTF recommends vision screening at least once in all<br>children aged 3 to 5 years to detect amblyopia or its risk<br>factors.   |
| Syphilis Screening  | Adolescents and<br>Adults | <ul> <li>USPSTF Rating (Sept. 2022): A         The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection             (asymptomatic, nonpregnant adults and adolescents who are at increased risk for syphilis infection).     </li> <li>USPSTF Rating (Sept. 2018): A         The USPSTF recommends early screening for syphilis     </li> </ul>   |
| Unhealthy Drug Use<br>Screening (Adults)  | Adults                    | <ul> <li>infection in all pregnant women.</li> <li>USPSTF Rating (June 2020): B</li> <li>The USPSTF recommends screening by asking questions about unhealthy drug use in adults aged 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)</li> </ul>  |
| Weight Loss to Prevent<br>Obesity-Related Morbidity<br>and Mortality in Adults:<br>Behavioral Interventions | Adults                    | <b>USPSTF Rating (Sept. 2018): B</b><br>The USPSTF recommends that clinicians offer or refer adults<br>with a body mass index (BMI) of 30 or higher (calculated as<br>weight in kilograms divided by height in meters squared) to<br>intensive multicomponent behavioral interventions.  |
| HRSA  | Supported Women           | 's Preventive Services Guidelines  |
| Breast Cancer Screening   | Women                     | Recommends that average-risk women initiate<br>mammography screening no earlier than age 40 and no later<br>than age 50. Screening mammography should occur at least<br>biennially and as frequently as annually. Screening should<br>continue through at least age 74 and age alone should not<br>be the basis to discontinue screening. Note: Women at<br>increased risk should also undergo periodic mammography<br>screening; however, recommendations for additional<br>services are beyond the scope of this recommendation. |
| Breastfeeding Services and Supplies   | Women                     | WPSI recommends comprehensive lactation support<br>services (including consultation; counseling; education by<br>clinicians and peer support services; and breastfeeding   |

|  | PREVENTIV  | E CARE SERVICES  |
|--|------------|--|
| (Newborns, Children, Adolescents and Adults) |            |  |
| Service                                      | Population | Summary  |
|  |            | equipment and supplies) during the antenatal, perinatal, and<br>postpartum periods to optimize the successful initiation and<br>maintenance of breastfeeding.  |
|  |            | Breastfeeding equipment and supplies include, but are not<br>limited to, double electric breast pumps (including pump<br>parts and maintenance) and breast milk storage supplies.<br>Access to double electric pumps should be a priority to<br>optimize breastfeeding and should not be predicated on<br>prior failure of a manual pump. Breastfeeding equipment<br>may also include equipment and supplies as clinically<br>indicated to support mother-infant dyads (pairs) with<br>breastfeeding difficulties and those who need additional<br>services.   |
| Contraception                                | Women      | <ul> <li>WPSI recommends that adolescent and adult women have access to the full range of contraceptives and contraceptive care to prevent unintended pregnancies and improve birth outcomes. Contraceptive care includes screening, education, counseling, and provision of contraceptives. Contraceptive care also includes follow-up care (e.g., management, evaluation and changes, including the removal, continuation, and discontinuation of contraceptives).</li> <li>WPSI recommends that the full range of U.S. Food and Drug Administration (FDA) approved, granted, or cleared contraceptives, effective family planning practices, and sterilization procedures be available as part of contraceptive care. The full range of contraceptives includes those currently listed in the FDA's Birth Control Guide: (1) sterilization surgery for women, (2) implantable rods, (3) copper intrauterine devices, (4) intrauterine devices with progestin (all durations and doses), (5) injectable contraceptives (progestin only), (8) oral contraceptives (extended or continuous use), (9) the contraceptive patch, (10) vaginal contraceptive rings, (11) diaphragms, (12) contraceptive sponges, (13) cervical caps, (14) condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraceptives approved, granted, or cleared by the FDA.</li> </ul> |
|  |            | Also, instruction in fertility awareness-based methods,<br>including the lactation amenorrhea method, should be<br>provided to women desiring an alternative method.   |

|  | PREVENTIV  | E CARE SERVICES  |
|--|------------|--|
| (Newborns, Children, Adolescents and Adults)                           |            |  |
| Service  | Population | Summary  |
| Counseling for Sexually<br>Transmitted Infections (STIs)               | Women      | WPSI recommends directed behavioral counseling by a<br>health care clinician or other appropriately trained individual<br>for sexually active adolescent and adult women at an<br>increased risk for STIs. WPSI recommends that clinicians<br>review a woman's sexual history and risk factors to help<br>identify those at an increased risk of STIs. Note: For<br>adolescents and women not identified as high risk,<br>counseling to reduce the risk of STIs should be considered,<br>as determined by clinical judgment.   |
| Obesity Prevention in Midlife<br>Women                                 | Women      | WPSI recommends counseling midlife women aged 40 to 60<br>years with normal or overweight body mass index (BMI)<br>(18.5-29.9 km/m2) to maintain weight or limit weight gain to<br>prevent obesity. Counseling may include individualized<br>discussion of healthy eating and physical activity.   |
| Screening and Counseling for<br>Interpersonal and Domestic<br>Violence | Women      | Recommends screening adolescents and women for<br>interpersonal and domestic violence, at least annually, and,<br>when needed, providing or referring for initial intervention<br>services. Interpersonal and domestic violence includes<br>physical violence, sexual violence, stalking and psychological<br>aggression (including coercion), reproductive coercion,<br>neglect, and the threat of violence, abuse, or both.<br>Intervention services include, but are not limited to,<br>counseling, education, harm reduction strategies, and<br>referral to appropriate supportive services. |
| Screening for Anxiety  | Women      | The Women's Preventive Services Initiative (WPSI)<br>recommends screening for anxiety in adolescent and adult<br>women, including those who are pregnant or postpartum.<br>Optimal screening intervals are unknown and clinical<br>judgement should be used to determine screening<br>frequency. Given the high prevalence of anxiety disorders,<br>lack of recognition in clinical practices, and multiple<br>problems associated with untreated anxiety, clinicians<br>should consider screening women who have not been<br>recently screened.   |
| Screening for Cervical Cancer  | Women      | Recommends cervical cancer screening for average-risk<br>women aged 21 to 65 years. For women aged 21 to 29 years<br>recommends cervical cancer screening using cervical<br>cytology (Pap test) every 3 years. Cotesting with cytology<br>and human papillomavirus testing is not recommended for<br>women younger than 30 years. Women aged 30 to 65 years<br>should be screened with cytology and human papillomavirus<br>testing every 5 years or cytology alone every 3 years.   |
| Screening for Diabetes After<br>Pregnancy                              | Women      | WPSI recommends screening for type 2 diabetes in women<br>with a history of gestational diabetes mellitus (GDM) who<br>are not currently pregnant and who have not previously<br>been diagnosed with type 2 diabetes. Initial testing should   |

| PREVENTIVE CARE SERVICES   |       |  |
|--|-------|--|
| (Newborns, Children, Adolescents and Adults)                     |       |  |
| Service Population Summary                                       |       |  |
|  |       | ideally occur within the first year postpartum and can be<br>conducted as early as 4–6 weeks postpartum. Women who<br>were not screened in the first year postpartum or those with<br>a negative initial postpartum screening test result should be<br>screened at least every 3 years for a minimum of 10 years<br>after pregnancy. For those with a positive screening test<br>result in the early postpartum period, testing should be<br>repeated at least 6 months postpartum to confirm the<br>diagnosis of diabetes regardless of the type of initial test<br>(e.g., fasting plasma glucose, hemoglobin A1c, oral glucose<br>tolerance test). Repeat testing is also indicated for women<br>screened with hemoglobin A1c in the first 6 months<br>postpartum regardless of whether the test results are<br>positive or negative because the hemoglobin A1c test is less           |
| Screening for Diabetes in<br>Pregnancy                           | Women | accurate during the first 6 months postpartum.<br>WPSI recommends screening pregnant women for<br>gestational diabetes mellitus after 24 weeks of gestation<br>(preferably between 24 and 28 weeks of gestation) to<br>prevent adverse birth outcomes. WPSI recommends<br>screening pregnant women with risk factors for type 2<br>diabetes or GDM before 24 weeks of gestation—ideally at<br>the first prenatal visit.  |
| Screening for Human<br>Immunodeficiency Virus<br>(HIV) Infection | Women | The Women's Preventive Services Initiative (WPSI)<br>recommends all adolescent and adult women, ages 15 and<br>older, receive a screening test for human immunodeficiency<br>virus (HIV) at least once during their lifetime. Earlier or<br>additional screening should be based on risk and rescreening<br>annually or more often may be appropriate beginning at age<br>13 for adolescent and adult women with an increased risk of<br>HIV infection. The WPSI recommends risk assessment and<br>prevention education for HIV infection beginning at age 13<br>and continuing as determined by risk. A screening test for<br>HIV is recommended for all pregnant women upon initiation<br>of prenatal care with rescreening during pregnancy based on<br>risk factors. Rapid HIV testing is recommended for pregnant<br>women who present in labor with an undocumented HIV<br>status. |
| Screening for Urinary<br>Incontinence                            | Women | WPSI recommends screening women for urinary<br>incontinence annually. Screening should ideally assess<br>whether women experience urinary incontinence and<br>whether it impacts their activities and quality of life. The<br>Women's Preventive Services Initiative recommends<br>referring women for further evaluation and treatment if<br>indicated.   |
| Well-Woman Exams   | Women | WPSI recommends that women receive at least one preventive care visit per year beginning in adolescence and  |

|  | PREVENTIVE                                   | CARE SERVICES  |  |
|--|--|--|--|
| (New   | (Newborns, Children, Adolescents and Adults) |  |  |
| Service Population Summary   |  |  |  |
|  |  | continuing across the lifespan to ensure the provision of all<br>recommended preventive services, including preconception<br>and many services necessary for prenatal and<br>interconception care, are obtained. The primary purpose of<br>these visits should be the delivery and coordination of<br>recommended preventive services as determined by age and<br>risk factors. These services may be completed at a single visit<br>or as part of a series of visits that take place over time to<br>obtain all necessary services. |  |
|  |  | ns for Preventive Pediatric Health Care  |  |
| Anemia Screening<br>Depression Screening                                 | Children<br>Children                         | Anemia screening in children up until the age of 22.<br>Depression screening at each of the recommended visits<br>between age 12-21 years.   |  |
|  |  | Note: Maternal depression screening for postpartum depression should be integrated into well-child visits at 1, 2, 4 and 6 months of age.  |  |
| Dyslipidemia Screening (Risk<br>Assessment/Screening Lab<br>Work)        | Children                                     | Risk Assessment recommended at 24 months, 4 years, 6<br>years, 8 years, 12 years, 13 years, 14 years, 15 years, 16<br>years.<br>Screening Lab Work - conduct if risk assessment is positive,<br>or, at the following intervals:  |  |
|  |  | <ul> <li>once between age 9-11 years;</li> <li>once between age 17-21 years.</li> </ul>  |  |
| Fluoride Application in<br>Primary Care – Prevention of<br>Dental Caries | Children                                     | For those at high risk, consider application of fluoride<br>varnish for caries prevention every 3 to 6 months, between<br>ages 6 months to 5 years.  |  |
| Formal<br>Developmental/Autism<br>Screening                              | Children                                     | Screening up until the age of 3.   |  |
| Hearing Tests  | Children                                     | <ul> <li>Hearing Tests - recommended at ages: Newborn; between 3-<br/>5 days to 2 months; 4 years; 5 years, 6 years; 8 years; 10<br/>years; once between age 11-14 years; once between age 15-<br/>17 years; once between age 18-21 years; also recommended<br/>for those that have a positive risk assessment.</li> <li>Risk Assessment - recommended at ages: 4 months, 6<br/>months, 9 months, 12 months, 15 months, 18 months, 24</li> </ul>   |  |
| HIV Screening  | Children                                     | months, 30 months, 3 years, 7 years, and 9 years.<br>HIV Risk Assessment: Conduct risk assessment at age 11  |  |
|  |  | years, 12 years, 13 years and 14 years.<br>HIV Screening Lab Work: Conduct once between age 15-21<br>years. Also, it is recommended anytime between ages 11-14   |  |
|  |  | years when a risk assessment is positive.  |  |

|  |                                   | E CARE SERVICES   |
|--|-----------------------------------|---|
| •  |                                   | , Adolescents and Adults)   |
| Service  | Population                        | Summary   |
| Lead Screening                                 | Children                          | Lead screening, from ages 6 months until the age of 7.  |
| Psychosocial/Behavioral<br>Assessment          | Children                          | Assessments recommended up until the age of 22.   |
| Screening for Visual<br>Impairment in Children | Children                          | Visual acuity screening is recommended for age 4 and 5<br>years as well as in cooperative 3-year-old children.<br>Instrument-based screening recommended for age 12 and<br>24 months, in addition to the well visits at 3-5 years of age.   |
| Sexually Transmitted<br>Infections (STI)       | Children                          | STI Risk Assessment: Conduct risk assessment at each of the recommended visits between 11 years – 21 years.   |
|  |                                   | STI Lab Work: Conduct if risk assessment is positive.   |
| Tobacco, Alcohol or Drug<br>Use Assessment     | Children                          | Assessments recommended from age 11-21 years.   |
| Tuberculosis Testing                           | Children                          | Testing until the age of 22.  |
| ACIP R   | ecommendations: Ro                | outine Immunizations for Children   |
| Chickenpox (Varicella)                         | Children<br>Children (6 months of | <ul> <li>Two doses of the chickenpox shot are recommended for children by doctors as the best way to protect against chickenpox (varicella).</li> <li>One dose at each of the following ages: <ul> <li>1<sup>st</sup> Dose: 12 – 15 months, and</li> <li>2<sup>nd</sup> Dose: 4 – 6 years.</li> </ul> </li> <li>Older children or adolescents should also get two doses of the chickenpox if they have never received a chickenpox shot or never had chickenpox. They should also get a second shot if they have had only one chickenpox shot.</li> </ul> |
| COVID-19 Vaccine                               | age and older)                    | See link for full details:<br><u>https://www.cdc.gov/vaccines/covid-19/downloads/COVID-</u><br><u>19-immunization-schedule-ages-6months-older.pdf</u>   |
| Diphtheria, Tetanus and<br>Pertussis (DTaP)    | Children                          | <ul> <li>Five doses of the DTaP shot and a Tdap booster shot are recommended for children and preteens by doctors as the best way to protect against diphtheria. Note: Protects against diphtheria, as well as tetanus and whooping cough (pertussis).</li> <li>Recommended cadence: <ul> <li>1<sup>st</sup> Dose: 2 months,</li> <li>2<sup>nd</sup> Dose: 4 months,</li> <li>3<sup>rd</sup> Dose: 6 months,</li> <li>4<sup>th</sup> Dose: 15 – 18 months,</li> </ul> </li> </ul>   |
|  |                                   | <ul> <li>5<sup>th</sup> Dose: 1 – 6 years, and</li> <li>6<sup>th</sup> Dose: 11 or 12 years (booster vaccine called Tdap).</li> </ul>   |

|  | PREVENTIVE | E CARE SERVICES   |
|--|------------|---|
| (Newborns, Children, Adolescents and Adults) |            |   |
| Service                                      | Population | Summary   |
| Haemophilus Influenzae<br>Type b (Hib)       | Children   | <ul> <li>Three or four doses, depending on the brand of the vaccine, are recommended for children by doctors as the best way to protect against Hib disease.</li> <li>One dose at each of the following ages: <ul> <li>1<sup>st</sup> Dose: 2 months,</li> </ul> </li> </ul>  |
|  |            | <ul> <li>2<sup>nd</sup> Dose: 4 months,</li> <li>3<sup>rd</sup> Dose: 6 months (for some brands), and</li> <li>4<sup>th</sup> Dose: 12 – 15 months.</li> </ul>  |
| Hepatitis A                                  | Children   | Two doses of the hepatitis A vaccine are recommended for<br>children by doctors as the best way to protect against<br>hepatitis A.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 12 – 23 months, and</li> <li>2<sup>nd</sup> Dose: 6 months after last dose.</li> </ul>   |
| Hepatitis B                                  | Children   | Three doses of the hepatitis B shot are recommended for<br>children by doctors as the best way to protect against<br>hepatitis B.   |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: Shortly after birth,</li> <li>2<sup>nd</sup> Dose: 1- 2 months, and</li> <li>3<sup>rd</sup> Dose: 6 - 18 months.</li> </ul>  |
| Human Papillomavirus (HPV)                   | Children   | <ul> <li>3<sup>rd</sup> Dose: 6 – 18 months.</li> <li>HPV vaccination is recommended at ages 11 – 12 years<br/>(Note: the vaccination can be given starting at 9 years, for<br/>special situations) to protect against cancers caused by HPV<br/>infection.</li> </ul>  |
|  |            | <ul> <li>Recommendations: <ul> <li>11 – 12 years:</li> <li>Two doses of the HPV shot are needed, 6 – 12 months apart.</li> <li>If the shots are given less than 5 months apart, a 3<sup>rd</sup> dose is needed.</li> </ul> </li> <li>If started after 15<sup>th</sup> birthday: <ul> <li>Three doses of the HPV shot should be given over 6 months.</li> </ul> </li> </ul> |
| Inactivated Poliovirus                       | Children   | Four doses of the polio shot for children are recommended<br>by doctors as the best way to protect against polio.   |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 2 months,</li> <li>2<sup>nd</sup> Dose: 4 months,</li> <li>3<sup>rd</sup> Dose: 6 - 18 months, and</li> <li>4<sup>th</sup> Dose: 4 - 6 years.</li> </ul>   |

|  | PREVENTIV  | 'E CARE SERVICES  |
|--|------------|---|
| (Newborns, Children, Adolescents and Adults) |            |   |
| Service                                      | Population | Summary   |
| Influenza (flu shot)                         | Children   | A yearly flu vaccine is the best way to protect your child from flu and its potentially serious complications.  |
|  |            | Doctors recommend children get a flu vaccine every year in<br>the fall, starting when he/she is 6 months old. Note: Some<br>children (6 months through 8 years of age) may need 2<br>doses for best protection.                       |
| Measles                                      | Children   | Two doses of the MMR vaccine are recommended for<br>children by healthcare providers as the best way to protect<br>against measles, mumps and rubella.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 12 – 15 months, and</li> <li>2<sup>nd</sup> Dose: 4- 6 years.</li> </ul>   |
| Meningococcal                                | Children   | Two doses of the meningococcal shot called MenACWY are recommended for preteens and teens by doctors as the best way to protect against meningococcal disease.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 11 – 12 years, and</li> <li>2<sup>nd</sup> Dose: 16 years.</li> </ul>  |
| Mumps  | Children   | Two doses of the MMR shot are recommended for children<br>by doctors as the best way to protect against measles,<br>mumps and rubella.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 12 – 15 months, and</li> <li>2<sup>nd</sup> Dose: 4 – 6 years.</li> </ul>  |
| Pneumococcal                                 | Children   | Four doses of the pneumococcal shot called PCV13 are recommended for children by doctors as the best way to protect against disease.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 2 months,</li> <li>2<sup>nd</sup> Dose: 4 months,</li> <li>3<sup>rd</sup> Dose: 6 months, and</li> <li>4<sup>th</sup> Dose: 12 – 15 months.</li> </ul> |
| Rubella                                      | Children   | Two doses of the MMR shot (measles, mumps and rubella)<br>are recommended for children by doctors as the best way to<br>protect against rubella.  |
|  |            | <ul> <li>One dose at each of the following ages:</li> <li>1<sup>st</sup> Dose: 12 – 15 months, and</li> <li>2<sup>nd</sup> Dose: 4 – 6 years.</li> </ul>  |

|  | PREVENTIV          | E CARE SERVICES   |
|--|--------------------|---|
| (Newborns, Children, Adolescents and Adults) |                    |   |
| Service                                      | Population         | Summary   |
| Rotavirus                                    | Children           | Two or more doses of a rotavirus are recommended for<br>children by doctors as the best way to protect against<br>rotavirus.  |
|  |                    | <ul> <li>Babies should get either of the two available rotavirus vaccines:</li> <li>RotaTeq<sup>®</sup> (RV5) is given in three doses at ages 2 months, 4 months and 6 months, or</li> <li>Rotarix<sup>®</sup> (RV1) is given in two doses at ages 2 months and 4 months.</li> </ul>                              |
|  |                    | Note: Both brands of the rotavirus vaccines are given by mouth (drops), not by shot.  |
| ACIP   | Recommendations: R | outine Immunizations for Adults   |
| Chickenpox (Varicella)                       | Adults             | If you aren't immune to chickenpox (if you haven't had<br>chickenpox in the past or been vaccinated against), you need<br>to get 2 doses of the vaccine about 1 month apart.  |
| COVID-19 Vaccine                             | Adults             | See link for full details:  |
|  |                    | https://www.cdc.gov/vaccines/covid-19/downloads/COVID-<br>19-immunization-schedule-ages-6months-older.pdf   |
| Diphtheria                                   | Adults             | All adults who have never received one should get a shot of<br>Tdap. This can be given at any time, regardless of when they<br>last got Td. This should be followed by either a Td or Tdap<br>shot every 10 years.  |
|  |                    | Note: Vaccines used today against diphtheria and tetanus<br>(i.e., DT and Td) sometimes also include protection against<br>whooping cough or pertussis (i.e., DTaP and Tdap). Babies<br>and children younger than 7 years old receive DTaP or DT,<br>while older children and <b>adults receive Tdap and Td</b> . |
| Flu (influenza)                              | Adults             | Recommended once a year.  |
| Haemophilus Influenzae<br>Type b (Hib)       | Adults             | 1 or 3 doses, depending on indication.  |
| Hepatitis A                                  | Adults             | Recommended for people at increased risk for hepatitis A,<br>people at increased risk for severe disease from hepatitis A,<br>pregnant women at risk for hepatitis A or risk for severe<br>outcome from hepatitis A infection and any person who<br>requests vaccination.   |
|  |                    | There are two types of hepatitis A vaccine. The first type, the single-dose hepatitis A vaccine, is given as two shots, 6 months apart, and both shots are needed for long-term protection against hepatitis A. The other type is a   |

|  | PREVENTIV  | E CARE SERVICES   |
|--|------------|---|
| (Newborns, Children, Adolescents and Adults) |            |   |
| Service                                      | Population | Summary   |
|  |            | combination vaccine that protects people against both<br>hepatitis A and hepatitis B. The combination vaccine can be<br>given to anyone 18 years of age and older and is given as<br>three shots over 6 months. All three shots are needed for<br>long-term protection for both hepatitis A and hepatitis B.  |
| Hepatitis B                                  | Adults     | Recommended for adults aged 19 through 59 years and<br>adults aged 60 years and older with risk factors for hepatitis<br>B. Note: Adults who are 60 years or older without known risk<br>factors for hepatitis B may also receive hepatitis B vaccine.  |
| Human Papillomavirus (HPV)                   | Adults     | <ul> <li>Teens and young adults who start the series later (see above, Immunizations - Children), at ages 15 through 26 years, need three doses of HPV vaccine.</li> <li>Vaccination is not recommended for everyone older than age 26 years. However, some adults aged 27 – 45 years and not already vaccinated may decide to get HPV vaccine after</li> </ul> |
| Measles                                      | Adults     | <ul><li>speaking with their doctor about their risk.</li><li>Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine.</li></ul>   |
| Meningococcal                                | Adults     | <ul> <li>There are 2 types of meningococcal vaccines available in the United States:</li> <li>Meningococcal conjugate or MenACWY vaccines (Menactra®, Menveo® and MenQuadfi®), and</li> <li>Serogroup B meningococcal or MenB vaccines (Bexsero®and Trumenba®).</li> <li>The CDC recommends:</li> </ul>   |
|  |            | <ul> <li>Routine MenACWY vaccination for adults at<br/>increased risk for meningococcal disease.</li> <li>Routine MenB vaccination for people 10 years or<br/>older at increased risk for meningococcal disease.</li> </ul>   |
| Mumps  | Adults     | Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine.  |
| Whooping Cough (Pertussis)                   | Adults     | Pregnant women should get Tdap during the early part of<br>the 3rd trimester of every pregnancy.<br>Also, all adults who have never received one should get a<br>shot of Tdap. This can be given at any time, regardless of<br>when they last got Td. This should be followed by either a Td<br>or Tdap shot every 10 years.                                    |
|  |            | Note: Vaccines used today against diphtheria and tetanus<br>(i.e., DT and Td) sometimes also include protection against<br>whooping cough or pertussis (i.e., DTaP  |

| PREVENTIVE CARE SERVICES<br>(Newborns, Children, Adolescents and Adults) |            |  |
|--|------------|--|
| Service  | Population | Summary  |
|  |            | and Tdap). Babies and children younger than 7 years old<br>receive DTaP or DT, while older children and <b>adults receive</b><br><b>Tdap and Td</b> .  |
| Pneumococcal   | Adults     | <ul> <li>There are two kinds of pneumococcal vaccines available in the United States:</li> <li>Pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20), and</li> <li>Pneumococcal polysaccharide vaccine (PPSV23).</li> </ul>  |
|  |            | For those who have never received any pneumococcal conjugate vaccine, the CDC recommends PCV15 or PCV20 for adults 65 years or older and adults 19 through 64 years old with certain medical conditions or risk factors. If PCV15 is used, this should be followed by a dose of PPSV23.  |
| Rubella  | Adults     | Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine.   |
| Shingles   | Adults     | The CDC recommends that adults 50 years and older get two<br>doses of the shingles vaccine called Shingrix (recombinant<br>zoster vaccine) to prevent shingles and the complications<br>from the disease. Adults 19 years and older who have<br>weakened immune systems because of disease or therapy<br>should also get two doses of Shingrix, as they have a higher<br>risk of getting shingles and related complications. |
|  |            | There is no maximum age for getting Shingrix.  |
| Tetanus  | Adults     | Pregnant women should get Tdap during the early part of the 3rd trimester of every pregnancy.  |
|  |            | All adults who have never received one should get a shot of Tdap. This can be given at any time, regardless of when they last got Td. This should be followed by either a Td or Tdap shot every 10 years.  |
|  |            | Note: Vaccines used today against diphtheria and tetanus<br>(i.e., DT and Td) sometimes also include protection against<br>whooping cough or pertussis (i.e., DTaP and Tdap). Babies<br>and children younger than 7 years old receive DTaP or DT,<br>while older children and <b>adults receive Tdap and Td</b> .  |

## **IMPORTANT INFORMATION:**

This document is intended as a reference tool and is not a guarantee of coverage nor payment. Covered services are only available to eligible members, in accordance with the guidelines addressed in the Evidence of Coverage (EOC). Please keep in mind, this document <u>includes federal requirements only</u> – national preventive care coverage – state required benefits are not addressed. *However, we do cover additional preventive care benefits when required by state law, see EOC for further details.* 

Ambetter from MHS is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in the Indiana Health Insurance Marketplace. This is a solicitation for insurance. © 2023 Celtic Insurance Company. All rights reserved.

#### Statement of Non-Discrimination

Ambetter from MHS is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in the Indiana Health Insurance Marketplace. Celtic Insurance Company complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin (including limited English proficiency and primary language), age, disability, or sex (including pregnancy, sexual orientation, gender identity, or sex characteristics). This is a solicitation for insurance. © 2023 Celtic Insurance Company. All rights reserved. <u>Ambetter.mhsindiana.com</u>

If you, or someone you are helping, have questions about Ambetter from MHS, and are not proficient in English, you have the right to get help and information in your language at no cost and in a timely manner. If you, or someone you are helping, have an auditory and/or visual condition that impedes communication, you have the right to receive auxiliary aids and services at no cost and in a timely manner. To receive translation or auxiliary services, please contact Member Services at 1-877-687-1182 (TTY 1-800-743-3333). If you believe that Celtic Insurance Company has failed to provide these services or discriminated in another way on the basis of race, color, national origin (including limited English proficiency and primary language), age, disability, or sex (including pregnancy, sexual orientation, gender identity, or sex characteristics), please contact Member Services at 1-877-687-1182 (TTY 1-800-743-3333). For information on filing a discrimination complaint directly with the U.S. Department of Health and Human Services, Office of Civil Rights, please visit <a href="https://ocrportal.hhs.gov/ocr/smartscreen/main.jsf">https://ocrportal.hhs.gov/ocr/smartscreen/main.jsf</a>.

| English:                | If you, or someone you are helping, have questions about Ambetter from MHS, and are not proficient in English, you have the right to get help and information in your language at no cost and in a timely manner. If you, or someone you are helping, have an auditory and/or visual condition that impedes communication, you have the right to receive auxiliary aids and services at no cost and in a timely manner. To receive translation or auxiliary services, please contact Member Services at 1-877-687-1182 (TTY 1-800-743-3333).   |
|-------------------------|--|
| Spanish:                | Si usted, o alguien a quien está ayudando, tiene preguntas acerca de Ambetter de MHS y no domina el inglés, tiene derecho a obtener ayuda e información en su idioma sin costo alguno y de manera oportuna. Si usted, o alguien a quien está ayudando, tiene un impedimento auditivo o visual que le dificulta la comunicación, tiene derecho a recibir ayuda y servicios auxiliares sin costo alguno y de manera oportuna. Va de manera oportuna. Para recibir servicios auxiliares o de traducción, comuníquese con Servicios para Miembros al 1-877-687-1182 (TTY 1-800-743-3333).  |
| Chinese:                | 如果您,或是您正在協助的對象,有關於Ambetter from MHS 方面的問題,且不精通英語,您有權利免費並及時以您的母語獲幫助<br>和訊息。如果您,或您正在協助的對象有聽力和/或視力上的問題,阻礙了溝通,您有權利免費並及時獲得輔助支援與服務。若要取<br>得翻譯或輔助服務,請聯絡會員服務部,電話是 1-877-687-1182 (TTY 1-800-743-3333)。   |
| German:                 | Falls Sie oder jemand, dem Sie helfen, Fragen zu Ambetter from MHS hat und nicht Englisch spricht, haben Sie das Recht,<br>kostenlos und zeitnah Hilfe und Informationen in Ihrer Sprache zu erhalten. Falls Sie oder jemand, dem Sie helfen, eine Hör-<br>und/oder Sehbeeinträchtigung hat, die die Kommunikation beeinflusst, haben Sie das Recht, kostenlos und zeitnah zusätzliche<br>Hilfe und Dienstleistungen zu erhalten. Um eine Übersetzung oder zusätzliche Dienstleistungen zu erhalten, wenden Sie sich an<br>den Kundendienst unter 1-877-687-1182 (TTY 1-800-743-3333).   |
| Pennsylvanian<br>Dutch: | Wann du, odder epper wer dir helft, hen Frooge iwwer Ambetter from MHS, un sin net proficient in Englisch, du hoscht die Recht<br>um Helf zu griege un Information in dei Schprooch mitaus Koscht un in en zeitlich Manner. Wann du, odder epper wer dir helft, hen<br>en Auditory un/odder Sehlich Condition die iss schlecht fer Communication, du hoscht die Recht Auxiliary Aids zu griege un<br>Services mitaus Koscht un in en zeitlich Manner. Fer Iwwersetzing odder Auxiliary Services zu griege, sei so gut un ruff Member<br>Services um 1-877-687-1182 (TTY 1-800-743-3333).   |
| Burmese:                | အကယ်၍ သင် သို့မဟုတ် သင်ကူညီနေသူတစ်ဦးသည် Ambetter from MHS အကြောင်းနှင့် ပတ်သက်၍ မေးခွန်းများ မေးလိုပြီး<br>အင်္ဂလိပ်လို ကျွမ်းကျင်စွာ မပြောနိုင်ပါက၊ သင့်တွင် အကူအညီနှင့် အချက်အလက်များကို သင့်ဘာသာစကားဖြင့် အခကြေးငွေ<br>ပေးစရာမလိုဘဲ အချိန်နှင့်တစ်ပြေးညီ ရယူပိုင်ခွင့်ရှိသည်။ အကယ်၍ သင် သို့မဟုတ် သင်ကူညီနေသူတစ်ဦးသည် ဆက်သွယ်ရေးကို<br>အဟန့်အတားဖြစ်စေသော အကြားအာရုံ နှင့်/သို့မဟုတ် အမြင်အာရုံနှင့် သက်ဆိုင်သော အခြေအနေတစ်ခုရှိပါက၊ သင့်တွင်<br>အရန်အကူအညီများနှင့် ဝန်ဆောင်မှုများကို အခကြေးငွေ ပေးစရာမလိုဘဲ အချိန်နှင့်တစ်ပြေးညီ ရယူပိုင်ခွင့်ရှိသည်။ ဘာသာပြန် သို့မဟုတ်<br>အရန်ဝန်ဆောင်မှုများကို လက်ခံရယူရန် 1-877-687-1182 (TTY 1-800-743-3333) ရှိ အဖွဲ့ဝင် ဝန်ဆောင်မှုများ ကို ဆက်သွယ်ပါ။ |
| Arabic:                 | إذا كان لديك أو لدى شخص تساعده أسئلة حول Ambetter from MHS، ولم تكن بارعًا باللغة الإنكليزية، فلديك الحق في الحصول على المساعدة والمعلومات بلغتك من دون أي<br>تكلفة وفي الوقت المناسب. إذا كنت أنت أو أي شخص تساعده تعاني من حالة سمعية و/أو بصرية تعيق التواصل، فلديك الحق في تلقي مساعدات وخدمات إضافية من دون أي تكلفة<br>وفي الوقت المناسب. لتلقي خدمات الترجمة أو خدمات إضافية، يرجى الاتصال بـ خدمات الأعضاء على (333-743-800) TTY) 218-787-687-182.   |
| Korean:                 | 귀하 또는 귀하의 도움을 받는 분이 Ambetter from MHS에 대한 질문이 있는 경우 영어에 능숙하지 않으시면 해당 언어로<br>시의적절하게 무료 지원과 정보를 받을 권리가 있습니다. 귀하 또는 귀하의 도움을 받는 분이 청각 및/또는 시각적으로 의사소통에<br>장애가 있는 경우 시의적절하게 무료 보조 도구 및 서비스를 받을 권리가 있습니다. 번역 또는 보조 서비스를 받으시려면 1-877-<br>687-1182(TTY 1-800-743-3333)번으로가입자 서비스부에 연락해주십시오.  |
| Vietnamese:             | Nếu quý vị hoặc người mà quý vị đang giúp đỡ có câu hỏi về Ambetter from MHS và không thành thạo tiếng Anh, quý vị có<br>quyền được trợ giúp và nhận thông tin bằng ngôn ngữ của mình miễn phí và kịp thời. Nếu quý vị hoặc người mà quý vị đang<br>giúp đỡ mắc bệnh về thính giác và/hoặc thị giác gây cản trở giao tiếp, quý vị có quyền được nhận các hỗ trợ và dịch vụ phụ trợ<br>miễn phí và kịp thời. Để nhận dịch vụ thông dịch hoặc dịch vụ phụ trợ, vui lòng liên hệ bộ phận Dịch Vụ Thành Viên theo số<br>1-877-687-1182 (TTY 1-800-743-3333).   |
| French:                 | Si vous-même ou une personne que vous aidez avez des questions à propos d'Ambetter from MHS et que vous ne maîtrisez pas<br>l'anglais, vous pouvez bénéficier gratuitement et en temps utile d'aide et d'informations dans votre langue. Si vous-même ou une<br>personne que vous aidez souffrez d'un trouble auditif ou visuel qui entrave la communication, vous pouvez bénéficier gratuitement et<br>en temps utile d'aides et de services auxiliaires. Pour profiter de services de traduction ou de services auxiliaires, veuillez contacter<br>Services aux membres au 1-877-687-1182 (TTY 1-800-743-3333).  |
| Japanese:               | ご自身やあなたが介護している他の人が、Ambetter from MHSについてご質問をお持ちの場合、英語に自信がなくても無料かつタ<br>イムリーにご希望の言語でヘルプや情報を得ることができます。ご自身や、あなたが介護している他の人の聴覚や視覚の状態のた<br>めやり取りが難しい場合でも、無料かつタイムリーに補助サービスを受けることができます。翻訳や補助サービスを受けるには、<br>1-877-687-1182 (TTY 1-800-743-3333)のメンバーサービスにご連絡ください。  |

| Dutch:   | Als u, of iemand die u helpt, vragen heeft over Ambetter from MHS en de Engelse taal niet machtig is, hebt u het recht om kosteloos en tijdig hulp en informatie in uw taal te krijgen. Als u, of iemand die u helpt, een auditieve en/of visuele beperking heeft die de communicatie belemmert, hebt u recht om kosteloos en tijdig hulpmiddelen en ondersteuning te ontvangen. Om vertaal- of ondersteuningsdiensten te ontvangen, kunt u contact opnemen met Ledenservice via 1-877-687-1182 (TTY 1-800-743-3333).  |
|----------|--|
| Tagalog: | Kung ikaw, o ang iyong tinutulungan, ay may mga katanungan tungkol sa Ambetter from MHS, at hindi ka mahusay sa Ingles,<br>may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika nang walang gastos at sa maagap na paraan. Kung<br>ikaw, o ang iyong tinutulungan, ay may kondisyon sa pandinig at/o paningin na nakakaapekto sa komunikasyon, may karapatan<br>kang makatanggap ng mga karagdagang tulong at serbisyo nang walang gastos at sa maagap na paraan. Para makatanggap<br>ng mga serbisyo sa pagsasalin o mga karagdagang serbisyo, mangyaring makipag-ugnayan sa Mga Serbisyo para sa<br>Miyembro sa 1-877-687-1182 (TTY 1-800-743-3333).                |
| Russian: | Если у вас или у лица, которому вы помогаете, возникли какие-либо вопросы о программе страхования Ambetter from<br>MHS, при этом вы недостаточно хорошо владеете английским языком, вы имеете право на бесплатную и своевременную<br>помощь и информацию на своем родном языке. Если у вас или у лица, которому вы помогаете, наблюдается какое-либо<br>нарушение слуха и/или зрения, которое препятствует коммуникации, вы имеете право на бесплатные и своевременные<br>вспомогательные услуги и помощь. Для получения услуг перевода или вспомогательных услуг обратитесь в отдел<br>обслуживания участников программы страхования по номеру 1-877-687-1182 (ТТҮ 1-800-743-3333). |
| Panjabi: | ਜੇ ਤੁਸੀਂ, ਜਾਂ ਤੁਹਾਡੇ ਦੁਆਰਾ ਮਦਦ ਕੀਤੇ ਜਾਣ ਵਾਲੇ ਕਿਸੇ ਵਿਅਕਤੀ ਦੇ Ambetter from MHS ਬਾਰੇ ਕੋਈ ਸਵਾਲ ਹਨ, ਅਤੇ ਤੁਸੀਂ ਅੰਗਰੇਜ਼ੀ ਵਿੱਚ ਮੁਹਾਰਤ ਨਹੀਂ ਰੱਖਦੇ<br>ਹੋ, ਤਾਂ ਤੁਹਾਨੂੰ ਆਪਣੀ ਭਾਸ਼ਾ ਵਿੱਚ ਬਿਨਾਂ ਕਿਸੇ ਕੀਮਤ ਦੇ ਅਤੇ ਸਮੇਂ ਸਿਰ ਮਦਦ ਅਤੇ ਜਾਣਕਾਰੀ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਧਿਕਾਰ ਹੈ। ਜੇ ਤੁਹਾਨੂੰ, ਜਾਂ ਤੁਹਾਡੇ ਦੁਆਰਾ ਮਦਦ ਕੀਤੇ<br>ਜਾਣ ਵਾਲੇ ਕਿਸੇ ਵਿਅਕਤੀ ਨੂੰ ਸੁਣਨ ਅਤੇ/ਜਾਂ ਦੇਖਣ ਸੰਬੰਧੀ ਕੋਈ ਸਮੱਸਿਆ ਹੈ, ਜੋ ਸੰਚਾਰ ਵਿੱਚ ਰੁਕਾਵਟ ਪਾਉਂਦੀ ਹੈ, ਤਾਂ ਤੁਹਾਨੂੰ ਬਿਨਾਂ ਕਿਸੇ ਕੀਮਤ ਅਤੇ ਸਮੇਂ ਸਿਰ ਸਹਾਇਕ<br>ਸਹਾਇਤਾ ਅਤੇ ਸੇਵਾਵਾਂ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਧਿਕਾਰ ਹੈ। ਅਨੁਵਾਦ ਜਾਂ ਸਹਾਇਕ ਸੇਵਾਵਾਂ ਪ੍ਰਾਪਤ ਕਰਨ ਲਈ, ਕਿਰਪਾ ਕਰਕੇ 1-877-687-1182 (TTY<br>1-800-743-3333) 'ਤੇ ਮੈਂਬਰ ਸੇਵਾਵਾਂ ਨਾਲ ਸੰਪਰਕ ਕਰੋ।   |
| Hindi:   | अगर आप या कोई ऐसा व्यक्ति जिसकी आप सहायता कर रहे हैं, के पास Ambetter from MHS से जुड़े प्रश्न हैं और आप दोनों अंग्रेज़ी में माहिर नहीं हैं,<br>तो आपको अपनी भाषा में मुफ़्त और समय पर सहायता और जानकारी प्राप्त करने का अधिकार है. अगर आपको या किसी ऐसे व्यक्ति को जिसकी आप<br>मदद कर रहे हैं, सुनने और/या देखने में समस्या होती है और इससे बातचीत बाधित होती है, तो आपको बिना किसी लागत के और समय पर सहायक<br>सहायता और सेवाएं प्राप्त करने का अधिकार है. अनुवाद या सहायक सेवाएं प्राप्त करने के लिए कृपया 1-877-687-1182 (TTY 1-800-743-3333) पर<br>सदस्य सेवाएं से संपर्क करें.  |

AMB23-IN-C-00057